$NDRA
ENDRA Life Sciences Inc. Stock $ndra

$ndra Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000165495423006594 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.594M	$1.548M	$1.642M
YoY Change	-7.53%	-5.74%	14.49%
% of Gross Profit
Research & Development	$1.400M	$1.391M	$1.213M
YoY Change	-24.21%	14.7%	6.27%
% of Gross Profit
Depreciation & Amortization	$35.27K	$34.52K	$19.04K
YoY Change	62.5%	81.3%	-39.42%
% of Gross Profit
Operating Expenses	$2.995M	$2.939M	$2.855M
YoY Change	-16.16%	2.94%	10.85%
Operating Profit	-$2.995M	-$2.939M	-$2.855M
YoY Change	-16.16%	2.94%	10.85%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$437.4K	-$3.418K	-$2.933K
YoY Change	-2357.84%	16.54%	-100.96%
Pretax Income	-$2.557M	-$2.943M	-$2.858M
YoY Change	-28.79%	2.96%	25.95%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.557M	-$2.943M	-$2.858M
YoY Change	-28.79%	2.96%	25.95%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.43	-$0.93	-$66.39K
COMMON SHARES
Basic Shares Outstanding	7.482M shares	3.169M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.819M	$2.355M	$7.127M
YoY Change	-57.27%	-66.95%	-57.68%
Cash & Equivalents	$4.819M	$2.355M	$7.127M
Short-Term Investments
Other Short-Term Assets	$506.9K	$428.5K	$1.061M
YoY Change	-39.28%	-59.63%	34.36%
Inventory	$2.758M	$2.735M	$1.930M
Prepaid Expenses	$506.9K	$428.5K	$1.061M
Receivables
Other Receivables
Total Short-Term Assets	$8.084M	$5.519M	$10.12M
YoY Change	-44.2%	-45.46%	-44.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$192.9K	$228.1K	$201.4K
YoY Change	-19.48%	13.25%	-63.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$536.1K	$438.3K	$5.986K
YoY Change	8855.06%	7222.59%
Total Long-Term Assets	$1.161M	$1.136M	$817.7K
YoY Change	41.25%	38.9%	48.67%
TOTAL ASSETS
Total Short-Term Assets	$8.084M	$5.519M	$10.12M
Total Long-Term Assets	$1.161M	$1.136M	$817.7K
Total Assets	$9.245M	$6.655M	$10.94M
YoY Change	-39.61%	-39.15%	-42.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$414.9K	$524.0K	$833.9K
YoY Change	-47.15%	-37.16%	85.3%
Accrued Expenses	$1.590M	$1.279M	$524.1K
YoY Change	121.61%	144.09%	63.78%
Deferred Revenue
YoY Change
Short-Term Debt	$28.48K	$0.00	$0.00
YoY Change
Long-Term Debt Due	$28.48K	$28.48K
YoY Change
Total Short-Term Liabilities	$2.033M	$1.832M	$1.358M
YoY Change	35.32%	34.89%	76.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$28.48K
YoY Change	-100.0%	-100.0%	-5.07%
Other Long-Term Liabilities	$281.2K	$324.1K	$481.6K
YoY Change	-36.7%	-32.71%	92.65%
Total Long-Term Liabilities	$281.2K	$324.1K	$510.1K
YoY Change	-40.52%	-36.47%	82.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.033M	$1.832M	$1.358M
Total Long-Term Liabilities	$281.2K	$324.1K	$510.1K
Total Liabilities	$2.314M	$2.156M	$1.868M
YoY Change	17.17%	15.41%	77.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$87.37M	-$84.81M	-$71.55M
YoY Change	16.28%	18.54%
Common Stock	$748.00	$317.00	$4.454K
YoY Change	-88.16%	-92.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.931M	$4.499M	$9.069M
YoY Change
Total Liabilities & Shareholders Equity	$9.245M	$6.655M	$10.94M
YoY Change	-39.61%	-39.15%	-42.13%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.557M	-$2.943M	-$2.858M
YoY Change	-28.79%	2.96%	25.95%
Depreciation, Depletion And Amortization	$35.27K	$34.52K	$19.04K
YoY Change	62.5%	81.3%	-39.42%
Cash From Operating Activities	-$2.269M	-$2.507M	-$3.099M
YoY Change	-31.98%	-19.1%	6.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$27.00K	$89.35K
YoY Change	-100.0%	-69.78%	98.56%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$27.00K	-$89.35K
YoY Change	-100.0%	-69.78%	98.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$854.1K
YoY Change			-91.28%
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	4.733M	$0.00	$854.1K
YoY Change	-37.28%	-100.0%	-93.21%
NET CHANGE
Cash From Operating Activities	-2.269M	-$2.507M	-$3.099M
Cash From Investing Activities	0.000	-$27.00K	-$89.35K
Cash From Financing Activities	4.733M	$0.00	$854.1K
Net Change In Cash	2.464M	-$2.534M	-$2.334M
YoY Change	-40.63%	8.55%	-124.28%
FREE CASH FLOW
Cash From Operating Activities	-$2.269M	-$2.507M	-$3.099M
Capital Expenditures	$0.00	$27.00K	$89.35K
Free Cash Flow	-$2.269M	-$2.534M	-$3.188M
YoY Change	-30.73%	-20.52%	7.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	ndra	Stock Payable StockPayable	3692	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84812648	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4499037	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6654888	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	428529	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	317	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	228139	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	469290	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-132002	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	90632	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3098870	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	89353	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-89353	usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001681682
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3169103	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3169103	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3169103	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	ndra	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37969
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ENDRA LIFE SCIENCES INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0579295
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3600 Green Court
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48105-1570
CY2023Q1	dei	City Area Code CityAreaCode	734
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	335-0468
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	NDRA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7481603	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2355251	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4889098	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	490299	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2735349	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2644717	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235655	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	505816	usd
CY2023Q1	ndra	Vendor Advance VendorAdvance	432344	usd
CY2022Q4	ndra	Vendor Advance VendorAdvance	502576	usd
CY2023Q1	ndra	Long Term Loan Amount LongTermLoanAmount	28484	usd
CY2022Q4	ndra	Long Term Loan Amount LongTermLoanAmount	28484	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3169103	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	317	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89307675	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89068015	usd
CY2022Q4	ndra	Stock Payable StockPayable	6073	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81869902	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7204504	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9274147	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1391314	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1213022	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	181616	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	339903	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1366398	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1302344	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2939328	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2855269	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2939328	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2855269	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3418	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2933	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3418	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2933	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2942746	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2858202	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2858202	usd
CY2023Q1	ndra	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.93
CY2022Q1	ndra	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-1.33
CY2023Q1	ndra	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	3169103	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10784246	usd
CY2022Q1	ndra	Common Stock Issued For Cash Net Of Funding Costs Amount CommonStockIssuedForCashNetOfFundingCostsAmount	854052	usd
CY2022Q1	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	288537	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	9068633	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7204504	usd
CY2023Q1	ndra	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	237279	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2942746	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4499037	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2942746	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-2858202	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	34516	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19038	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	237279	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	288537	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	36526	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	33179	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-286597	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	645680	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	122737	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-190597	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-36529	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-31742	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2506847	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	854052	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	854052	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2533847	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2334171	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4889098	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9461534	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2355251	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7127363	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023Q1	ndra	Stock Dividend Payable StockDividendPayable	2381	usd
CY2022Q1	ndra	Stock Dividend Payable StockDividendPayable	5089	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	469290	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	610234	usd
CY2023Q1	ndra	Lease Liability LeaseLiability	481618	usd
CY2022Q1	ndra	Lease Liability LeaseLiability	618735	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.</p>
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	410358	shares
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	469290	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	505816	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	481618	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	518147	usd
CY2023Q1	ndra	Research And Development Expense1 ResearchAndDevelopmentExpense1	1391314	usd
CY2022Q1	ndra	Research And Development Expense1 ResearchAndDevelopmentExpense1	1213022	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	665104	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	665104	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	410358	shares
CY2023Q1	ndra	Shares Available For Issuance Increased Under The Omnibus Plan SharesAvailableForIssuanceIncreasedUnderTheOmnibusPlan	867966	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	454203	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1322169	shares
CY2023Q1	us-gaap	Cumulative Dividends CumulativeDividends	84812648	usd
CY2023Q1	ndra	Working Capital WorkingCapital	3687342	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2735349	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2644717	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	765720	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	738720	usd
CY2023Q1	us-gaap	Development In Process DevelopmentInProcess	140617	usd
CY2022Q4	us-gaap	Development In Process DevelopmentInProcess	140617	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	678198	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	643682	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	228139	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	235655	usd
CY2023Q1	us-gaap	Depreciation Depreciation	34516	usd
CY2022Q1	us-gaap	Depreciation Depreciation	19038	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	524027	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	613961	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	216426	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	60638	usd
CY2023Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	815794	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	683738	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5750	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5750	usd
CY2023Q1	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	83752	usd
CY2022Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	158925	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1645749	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1523012	usd
CY2023Q1	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	90000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3169103	shares
CY2023Q1	ndra	Series A Preferred Stock SeriesAPreferredStock	141397	shares
CY2023Q1	ndra	Stock Payable Share StockPayableShare	3692	usd
CY2023Q1	ndra	Aggregate Fair Value Of Stock Options Granted AggregateFairValueOfStockOptionsGranted	1017235	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.06	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0368	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	53809	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	52763	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	391902	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.47
CY2023Q1	ndra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y4M28D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	273878	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.02
CY2023Q1	ndra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y10M2D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	19131	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	646649	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.69
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M4D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	234763	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.81
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10D
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	147541	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	202624	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	202624	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	552788	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	71171	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	481618	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	157554	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	324064	usd

Files In Submission

Name	View Source	Status
0001654954-23-006594-index-headers.html	Edgar Link	pending
0001654954-23-006594-index.html	Edgar Link	pending
0001654954-23-006594.txt	Edgar Link	pending
0001654954-23-006594-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ndra-20230331.xsd	Edgar Link	pending
ndra_10q.htm	Edgar Link	pending
ndra_ex311.htm	Edgar Link	pending
ndra_ex312.htm	Edgar Link	pending
ndra_ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
ndra-20230331_cal.xml	Edgar Link	unprocessable
ndra-20230331_pre.xml	Edgar Link	unprocessable
ndra_10q_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ndra-20230331_def.xml	Edgar Link	unprocessable
ndra-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NDRA
ENDRA Life Sciences Inc. Stock $ndra

2023 Q2 Form 10-Q Financial Statement

#000165495423006594 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NDRA ENDRA Life Sciences Inc. Stock $ndra

2023 Q2 Form 10-Q Financial Statement

#000165495423006594 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NDRA
ENDRA Life Sciences Inc. Stock $ndra